Capricor Therapeutics, Inc. Overview
Pro stress-test →Capricor Therapeutics is a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, with lead product Deramiocel, an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD). The company is advancing toward regulatory approval with a clear path through FDA review and significant clinical validation.
Strategic Profile
Pro stress-test →Deramiocel has demonstrated potent immunomodulatory and anti-fibrotic effects in helping preserve cardiac and skeletal muscle function in DMD. Capricor is leveraging its proprietary StealthX™ platform in preclinical development focused on vaccinology and targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, positioning the company as a multi-pipeline platform player in regenerative medicine.
Competitive Landscape
Pro stress-test →Capricor operates in the rare disease and regenerative medicine space, competing against other DMD therapeutic developers. The company's cell therapy platform with demonstrated Phase 3 clinical efficacy differentiates it from small molecule and gene therapy approaches. Limited direct competitors with validated Phase 3 cell therapies for DMD at comparable development stage.
Industry Context
Capricor Therapeutics, Inc. operates in Biotechnology - Regenerative Medicine & Cell Therapy.
Key facts
Headquarters: San Diego, United States